Erxian decoction inhibits apoptosis by activating Akt1 and repairs spinal cord injury in rats.

ABSTRACT:

Objective

Spinal cord injury (SCI) often leads to severe physiological and pathological changes in patients. Erxian Decoction (EXD) is effective in the postoperative treatment of spinal cord injury, but its specific mechanism of action is poorly defined.

Methods

Network pharmacology and molecular docking were used to predict the potential mechanisms of EXD in SCI. In vivo studies were used to validate the above predictions. For in vivo study, the rats were pretreated with or without EXD (5.76 g/kg, by intragastric gavage). Multiple molecular biological test methods to identify molecular mechanisms. One-way analysis of variance (ANOVA) was used with Bonferroni's post-hoc test to identify the differences between groups.

Results

In vivo studies have

SUBMITTER: Li E 

PROVIDER: S-EPMC9641199 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature